BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22937028)

  • 21. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer.
    Yang X; Zhang Q; Zhang M; Su W; Wang Z; Li Y; Zhang J; Beer DG; Yang S; Chen G
    Int J Biol Sci; 2019; 15(8):1712-1722. PubMed ID: 31360113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Down-regulated microRNA-375 expression as a predictive biomarker in non-small cell lung cancer brain metastasis and its prognostic significance.
    Chen LJ; Li XY; Zhao YQ; Liu WJ; Wu HJ; Liu J; Mu XQ; Wu HB
    Pathol Res Pract; 2017 Aug; 213(8):882-888. PubMed ID: 28688608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-small cell lung cancer associated microRNA expression signature: integrated bioinformatics analysis, validation and clinical significance.
    Li C; Yin Y; Liu X; Xi X; Xue W; Qu Y
    Oncotarget; 2017 Apr; 8(15):24564-24578. PubMed ID: 28445945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non-small cell lung cancer.
    Yoon KA; Yoon H; Park S; Jang HJ; Zo JI; Lee HS; Lee JS
    J Thorac Cardiovasc Surg; 2012 Oct; 144(4):794-807. PubMed ID: 22818121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
    Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
    Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macrophage-derived exosome promotes regulatory T cell differentiation in malignant pleural effusion.
    Shao MM; Pei XB; Chen QY; Wang F; Wang Z; Zhai K
    Front Immunol; 2023; 14():1161375. PubMed ID: 37143656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of MiRNA-221 in non-small cell lung cancer tissues and correlation with prognosis].
    Lv J; Xu L; Xu Y; Qiu M; Yang X; Wang J; Yin R; Xu L
    Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):221-5. PubMed ID: 24667259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-regulation of microRNA-126 and microRNA-133b acts as novel predictor biomarkers in progression and metastasis of non small cell lung cancer.
    Chen SW; Wang TB; Tian YH; Zheng YG
    Int J Clin Exp Pathol; 2015; 8(11):14983-8. PubMed ID: 26823832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of microRNA-based signatures for response and survival for non-small cell lung cancer treated with cisplatin-vinorelbine A ELCWP prospective study.
    Berghmans T; Ameye L; Willems L; Paesmans M; Mascaux C; Lafitte JJ; Meert AP; Scherpereel A; Cortot AB; Cstoth I; Dernies T; Toussaint L; Leclercq N; Sculier JP;
    Lung Cancer; 2013 Nov; 82(2):340-5. PubMed ID: 24007627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of recurrence-related microRNAs in hepatocellular carcinoma following liver transplantation.
    Han ZB; Zhong L; Teng MJ; Fan JW; Tang HM; Wu JY; Chen HY; Wang ZW; Qiu GQ; Peng ZH
    Mol Oncol; 2012 Aug; 6(4):445-57. PubMed ID: 22552153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC).
    Liao J; Shen J; Leng Q; Qin M; Zhan M; Jiang F
    Thorac Cancer; 2020 Mar; 11(3):762-768. PubMed ID: 31994346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer.
    Kanaoka R; Iinuma H; Dejima H; Sakai T; Uehara H; Matsutani N; Kawamura M
    Oncology; 2018; 94(5):311-323. PubMed ID: 29533963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer.
    Wang K; Chen M; Wu W
    World J Surg Oncol; 2017 Sep; 15(1):175. PubMed ID: 28927412
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating miRNA-21 and miRNA-23a Expression Signature as Potential Biomarkers for Early Detection of Non-Small-Cell Lung Cancer.
    Hetta HF; Zahran AM; Shafik EA; El-Mahdy RI; Mohamed NA; Nabil EE; Esmaeel HM; Alkady OA; Elkady A; Mohareb DA; Hosni A; Mostafa MM; Elkady A
    Microrna; 2019; 8(3):206-215. PubMed ID: 30652656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of Circulating miRNA-17 and miRNA-222 Expression Profiles as Non-Invasive Biomarkers in Egyptian Patients with Non-Small-Cell Lung Cancer.
    Hetta HF; Zahran AM; El-Mahdy RI; Nabil EE; Esmaeel HM; Elkady OA; Elkady A; Mohareb DA; Mahmoud Mostafa M; John J
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1927-1933. PubMed ID: 31244320
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer.
    Khandelwal A; Seam RK; Gupta M; Rana MK; Prakash H; Vasquez KM; Jain A
    Cancer Sci; 2020 Mar; 111(3):826-839. PubMed ID: 31520555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.
    Du L; Schageman JJ; Irnov ; Girard L; Hammond SM; Minna JD; Gazdar AF; Pertsemlidis A
    J Exp Clin Cancer Res; 2010 Jun; 29(1):75. PubMed ID: 20624269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma.
    Gao X; Wu Y; Yu W; Li H
    Oncotarget; 2016 Dec; 7(49):81670-81679. PubMed ID: 27835574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer.
    Morgensztern D; Waqar S; Subramanian J; Trinkaus K; Govindan R
    J Thorac Oncol; 2012 Oct; 7(10):1485-9. PubMed ID: 22982649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
    Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.